Obesity, Underweight and Dosing: — Does Your Body Size Change the Dose?

Yes, it can. Your weight is recorded before each cycle, and if it has changed by a meaningful amount your oncologist or pharmacist will recalculate. Weight shifts during treatment are common — some drugs cause fluid retention, others affect appetite. How much change triggers a recalculation depends on the drug and the protocol. Ask your team what they watch for on your specific regimen.

Yes, that is consistent with current ASCO guidance for BSA-based chemotherapy. Using actual body weight rather than a calculated ideal is now the recommended approach for most regimens in obese patients. The older practice of capping at an estimated ideal weight fell out of favour after evidence suggested it risked undertreating the cancer. If you want to understand how your dose was arrived at, ask your oncologist or the pharmacist preparing your infusion — both should be able to explain it.

Being underweight does increase the risk that side effects will be harder to tolerate, because your body has less nutritional reserve to draw on. This does not mean treatment is withheld — it means your team will watch more closely, may adjust the dose if the first cycle is poorly tolerated, and may involve a dietitian alongside treatment. Tell your team about any difficulty eating before your first infusion, not after. The earlier they know, the more they can do.

Usually yes. Many targeted therapies and most checkpoint inhibitor immunotherapy agents are given as flat doses — the same amount for every patient regardless of body size. This is a deliberate design based on how those drugs behave and how they were studied in clinical trials. For these treatments, your weight has less direct effect on what you receive. Your team will still monitor for side effects and adjust if needed.

Body surface area is a number combining your height and weight into a single figure, roughly representing your estimated external skin surface. It is calculated by a standard mathematical formula. Your oncology pharmacist does this calculation before each cycle — you do not need to work it out yourself. It is used instead of weight alone because it tends to track how your body distributes and processes drugs more reliably than weight by itself.

Deliberately restricting your diet in the weeks before starting treatment is not recommended. Losing weight quickly before chemotherapy can deplete exactly the reserves your body needs to tolerate it. If your surgeon or oncologist has specifically asked you to lose weight before a planned procedure — usually for a surgical or anaesthetic reason — follow that advice. Otherwise, focus on eating well and maintaining your strength. Raise any concerns about weight directly with your oncologist.

Often more so. Many cancer drugs are processed by the liver or cleared by the kidneys. If either organ is not working well, a standard dose can accumulate to toxic levels. Your team will check kidney and liver function before treatment starts and usually before each cycle. A dose reduction because of impaired organ function is separate from a weight-based adjustment — both can apply at the same time, and your pharmacist accounts for both when preparing your dose.

It can, for some drug classes and some side effects. Obesity is associated with a higher baseline risk of certain toxicities, including cardiovascular effects from particular agents. At the same time, being overweight does not automatically mean worse outcomes — the picture depends on the specific drug, your other medical conditions, and your overall fitness. What consistently matters most is accurate dosing and close monitoring through each cycle, not weight change before treatment starts.